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Background/Aims: Although early recognition and 
treatment with effective antibiotics have lead to im-
provements in the prognosis of patients with sponta-
neous bacterial peritonitis (SBP), it remains to be a 
serious complication in cirrhotic patients. This study 
was designed to evaluate the clinical manifestations 
and prognosis of patients with liver cirrhosis and SBP 
in Korea. Methods: This was a multicenter retro-
spective study examining 157 episodes of SBP in 145 
patients with cirrhosis. SBP was diagnosed based on 
a polymorphonuclear cell count in ascitic fluid of ＞
250 cells/mm3 in the absence of data compatible with 
secondary peritonitis. Results: The mean age of the 
cohort was 56 years, and 121 (77%) of the 157 epi-
sodes of SBP occurred in men. Microorganisms were 
isolated in 66 episodes (42%): Gram-negative bacteria 
in 54 (81.8%), Gram-positive in 11 (16.7%), and Can-
dida in 1. Isolated Gram-negative organisms were re-
sistant to third-generation cephalosporin in 6 cases 
(17%), to ciprofloxacin in 11 (20.8%), and to penicillin 
in 33 (62.3%). The treatment failure and in-hospital 
mortality rates were 12.1% and 21%, respectively. A 
high Model of End-Stage Liver Disease (MELD) score, 
SBP caused by extended-spectrum β-lactamase-pro-
ducing organisms, and hepatocellular carcinoma were 
independent prognostic factors of high in-hospital mor-
tality. Conclusions: SBP remains to be a serious 
complication with high in-hospital mortality, especially 
in patients with a high MELD score. (Gut and Liver 
2009;3:197-204)
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INTRODUCTION
  Patients with liver cirrhosis are vulnerable to bacterial 
infections due to defects in various host defense mecha-
nism.1,2 Spontaneous bacterial peritonitis (SBP) is the 
most common infection in cirrhotic patients followed by 
urinary tract infections, pneumonia, and bacteremia.3 SBP 
occurs in 8-27% of hospitalized patients with cirrhosis 
and ascites.1,4 Although the precise pathogenesis of SBP 
has not been clearly defined, overgrowth and translocation 
of intestinal bacteria, especially aerobic Gram-negative ba-
cilli, appears to be the most important step in the patho-
genic process.5-8 In addition, porto-systemic shunt, a low 
level of serum complement, and decreased neutrophil che-
motaxis may contribute to the development of bacteremia, 
and finally to the bacterial colonization of ascites.9-11 A 
high Child-Pugh score, a low protein level in ascites, and 
a high level of serum bilirubin have been previously iden-
tified to be risk factors for the development of SBP.5,12-14
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  When SBP was initially described in the English medi-
cal literature in the 1960s, its prognosis was extremely 
poor, with in-hospital mortality of 100%.15,16 However, re-
cently, the outcome of SBP has been considerably im-
proved due to early diagnosis and the introduction of ef-
fective antibiotics. Currently, the infection resolution 
rates are 77-91% and in-hospital mortalities 21-31%.17-21 
In addition, the appropriate management of renal impair-
ment in end-stage liver disease has been shown to further 
ameliorate the prognosis of SBP; a recent study concluded 
that the intravenous infusion of albumin in combination 
with cefotaxime reduced in-hospital mortality to 10%.22
  Together with its grave short-term prognosis, re-
currence rate after the resolution of an acute event may 
be as high as 70% during the subsequent year, and this 
remains as a challenging issue in the management of 
SBP.13 Thus, the oral administration of antibiotics such as 
quinolones and trimethoprim/sulfamethoxazole have been 
attempted to selectively achieve the intestinal decontami-
nation of mainly aerobic Gram-negative bacilli, and such 
trials have significantly reduced the rate of recurrence and 
initial occurrence of SBP.23-26 However, prolonged anti-
biotic prophylaxis is accompanied by risks of altering bac-
terial species and of selecting antibiotic resistant organ-
isms within the gut25,27 and may ultimately lead to mod-
ifications in causative microorganisms. Actually in a re-
cent study, half of SBP cases despite the long-term nor-
floxacin prophylactic use were found to be caused by qui-
nolone-resistant Gram- negative bacilli whereas only 16% 
of those not receiving prophylactic antibiotics were in-
fected by the resistant organism.3
  In addition, the misuse and overuse of broad spectrum 
antibiotics in general clinical practice has increased anti-
biotic-resistant microorganisms in many countries, which 
has raised concerns about potentially serious future clin-
ical problems.28-30 In fact, one Korean study reported that 
the prevalences of microorganisms resistant to third-gen-
eration cephalosporins and quinolones were increasing in 
cirrhotic patients with SBP and that they exerted a neg-
ative influence on prognosis.31
  In view of these expected changes regarding the cause 
and outcome of SBP, this multicenter retrospective study 
was performed to investigate the current status of SBP in 
Korea with specific regard to its microbiological features, 
treatment response and prognosis.
MATERIALS AND METHODS
1. Patients
  All patients with liver cirrhosis hospitalized for SBP 
treatment to 9 tertiary medical centers between June 
2005 and May 2006 were included in this retrospective 
study. A diagnosis of cirrhosis was established using his-
tologic criteria or by clinical and ultrasonographic fin-
dings. SBP was diagnosed based on a polymorphonuclear 
(PMN) cell count in ascitic fluid of ≥250 cells/mm3 in 
the absence of clinical and radiological findings suggestive 
of secondary peritonitis.32 Secondary bacterial peritonitis 
was suspected when two or more organisms were isolated 
from ascites or when the ascitic PMN count was ≥250 
cells/mm3 and at least two of the following three ascitic 
fluid findings were present: glucose ＜50 mg/dL; total 
protein ＞1 g/dL; and lactate dehydrogenase＞the upper 
limit of normal for serum.33 SBP was considered as com-
munity acquired when it was present at admission, and 
as hospital-acquired when it was developed ＞48 hours 
after admission.34 Patients who had taken oral quinolone 
for more than 1 month before the episode of SBP were 
allocated to the previous prophylaxis group. Renal impair-
ment at SBP diagnosis was defined as a serum creatinine 
＞1.5 mg/dL.
2. Bacterial culture
  Diagnostic paracentesis with ascitic fluid culture was 
performed in all patients with ascites who developed local 
symptoms or signs suggestive of peritoneal infection, sys-
temic signs of infection such as fever or leukocytosis, or 
clinical deterioration without any obvious precipitating 
factor. When an ascitic PMN count was greater than or 
equal to 250 cells/mm3, blood culture was performed.
  Ascitic fluid and peripheral blood were inoculated into 
aerobic and anaerobic blood-culture bottles (BACTEC NR 
600; Becton Dickinson, Sparks, MD, USA) at bedside.35 
At least 10 mL of ascitic fluid was inoculated into each 
bottle for aerobic and anaerobic cultures.35 All isolated or-
ganisms in culture were tested for antimicrobial suscepti-
bility according to the diffusion method.36
3. Treatment response and prognosis
  SBP resolution was considered when all signs of in-
fection had disappeared and PMN count in ascitic fluid 
had reduced to ＜250 cells/mm3. Treatment failure was 
defined as a decrease of ＜25% in PMN count after 48 
hours of treatment or a persistent PMN count of ＞250 
cells/mm3 on the 7th day of treatment, a positive culture 
after 48 hours of treatment, failure to continue antibiotic 
treatment, or persistent clinical signs of infection. Pati-
ents who died before follow-up paracentesis for the as-
sessment of treatment effect were also classified as having  
treatment failures. In-hospital mortality was defined as 
death from any cause during hospitalization.
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Table 1. Baseline Characteristics of the Study Cohort
n=157
Age (years)*  56±12
Men/women 121/36
Hospital-acquired, n (%)  31 (19.6)
Cause of cirrhosis, n (%)
  Hepatitis B virus 112 (71.3)
  Hepatitis C virus  10 (6.4)
  Alcohol abuse  31 (19.7)
  Others   4 (2.5)
Child-Pugh score*  11±2
Child-Pugh grade, n (%)
  B  35 (22.3)
  C 122 (77.7)
MELD score*  21.5±7.6
Hepatocellular carcinoma, n (%)  61 (38.9)
Portal vein invasion, n (%)  23 (14.6)
Patients with previous SBP, n (%)  36 (22.9)
Clinical manifestation, n (%)
  Renal impairment
†
 42 (26.8)
  Gastrointestinal hemorrhage  32 (20.4)
  Hepatic encephalopathy  43 (27.4)




Defined as a serum creatinine ＞1.5 mg/dL.
Table 2. Profiles of Isolated Microorganisms of the Enrolled 
Patients
Isolated microorganisms (n=66) No. (%)
Gram-negative organisms 54 (81.8)
  Escherichia coli 32 (48.5)
  Klebsiella pneumoniae 13 (19.7)
  Klebsiella oxytoca  2 (3.0)
  Aeromonas  4 (6.1)
  Pseudomonas  2 (3.0)
  Citrobacter freundii  1 (1.5)
Gram-positive organisms 11 (16.7)
  Streptococcus pneumoniae  2 (3.0)
  Streptococcus viridans  2 (3.0)
  Streptococcus salivarius  1 (1.5)
  Streptococcus tutermidius  1 (1.5)
  Staphylococcus aureus  1 (1.5)
  Staphylococcus hominis  1 (1.5)
  Coagulase (-) staphylococci  2 (3.0)
  Enterococcus faecium  1 (1.5)
Candida albicans  1 (1.5)
4. Statistical analysis
  Data are expressed as means±standard deviation (SD). 
Comparisons between groups were performed using the 
Student’s t test for quantitative data and using the χ2 
test or Fisher’s Exact Test for categorical data. Cumula-
tive mortality and cumulative SBP recurrence rate were 
calculated using Kaplan-Meier analysis.
  Univariate analysis was used to identify factors predict-
ing in-hospital mortality. Tested variables included age, 
sex, cause of cirrhosis, concomitant hepatocellular carci-
noma (HCC), SBP, cirrhosis-related clinical and laboratory 
data obtained at the time of diagnosis of infection 
(including Child-Pugh and model for end-stage liver dis-
ease [MELD] scores37), other standard laboratory data, 
and source of SBP infection (community vs nosocomial). 
The MELD score was calculated using the following for-
mula according to the method used by the United 
Network of Organ Sharing (http://www.unos.org): 9.57× 
loge (creatinine, mg/dL)+3.78×loge (bilirubin, mg/dL)+ 
11.20×loge (INR)+ 6.43. Variables that had statistical sig-
nificance (p＜0.05) by univariate analyses were subjected 
to multivariate analysis using a step-wise binary logistic 
regression procedure to identify independent predictors of 
survival. Odds ratios (ORs) and 95% confidence intervals 
(CIs) were calculated to determine significance by multi-
variate analysis. p-values of ＜0.05 were considered stat-
istically significant. All analyses were performed using 
SPSS version 10.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
1. Baseline characteristics
  This study included 157 episodes of SBP which devel-
oped in 145 patients with liver cirrhosis. Baseline charac-
teristics of the enrolled cases at SBP diagnosis are pre-
sented in Table 1. Mean patient age was 56±12 years and 
males predominated (77.1%). The most common cause of 
liver cirrhosis was chronic hepatitis B (71.3%), which was 
followed by alcohol abuse (19.7%) and chronic hepatitis 
C (6.4%). According to the Child-Pugh classification, 
22.3% and 77.7% were grades B and C, respectively; no 
patients had Child-Pugh grade A. The mean MELD score 
was 21.5±7.6. At time of SBP diagnosis, 61 cases 
(38.9%) had HCC, and portal vein thrombosis was noted 
in 23 cases (14.6%). Thirty-six cases (22.9%) had a his-
tory of at least one episode of previous SBP and 10 
(27.8%) had received prophylactic antibiotics to prevent 
SBP recurrence. Twenty-nine cases (18.5%) were nosoco-
mial and 128 cases were community-acquired.
2. Isolation of causative organisms and antibiotic- 
resistance
  Causative organisms were isolated from ascitic fluid or 
peripheral blood in 66 cases (42%). Table 2 presents a 
profile of the organisms isolated. Gram-negative organ-
isms accounted for 81.8% of all isolated organisms (54 of 
66 cases). Escherichia coli was the most frequently isolated 
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Age (years)  56±12  55±12 0.827
Sex, males (%) 4 (33.3%) 12 (22.6%) 0.643
Patients with Child-Pugh grade C, n (%) 8 (66.7%) 46 (86.8%) 0.093
Child-Pugh score 10.4±1.5 11.8±2.1 0.04
MELD score 18.3±6.1 23.1±7.7 0.048
Ascitic fluid
  Protein (g/dL) 1.33±0.65 0.92±0.52 0.025
  Albumin (g/dL) 0.50±0.29 0.45±0.27 0.549
Treatment failure to first-line antibiotics, n (%) 2 (18.2%) 10 (18.5%) 0.559
In-hospital mortality 1/12 (8.3%) 14/53 (26.4%) 0.179
Data are presented as means±S.D. or n (%).
*p-values were determined using the Student’s t-test or the chi-square test.
Table 4. Antibiotic Resistance Profiles of Isolated Organisms
n Cefotaxime* Ciprofloxacin* Ampicillin* ESBL*
Gram-negative organisms
  Escherichiae coli 32 5 (15.6) 10 (31.3) 17 (53.1) 5 (15.6)
  Klebsiella pneumoniae 13 1 (7.7)  1 (7.7) 11 (84.6) 1 (7.7)
  Klebsiella oxytoca 2 0  0  2 (100) 0
  Aeromonas 4 0  0  2 (50) 0
  Pseudomonas 2 0  0  1 (50) 0
  Citrobacter freundii 1 0  0  0 0
Gram-positive organisms
  Streptococcus pneumoniae 2 0  0  1 (50) 0
  Streptococcus viridans 2 0  1 (50)  0 0
  Streptococcus salivarius 1 0  0  0 0
  Streptococcus tutermidius 1 0  0  0 0
  Staphylococcus aureus 1 0  0  0 0
  Staphylococcus hominis 1 0  0  1 (100) 0
  Coagulase (-) staphylococci 2 0  0  1 (50) 0
  Enterococcus faecium 1 1 (100)  1 (100)  1 (100) 0
ESBL, extended-spectrum β-lactamase.
*n (%).
organism (32 of the 66 cases, 48.5%), followed by Kleb-
siella pneumoniae (13 cases, 19.7%) and Aeromonas species 
(4 cases, 6.1%). Gram-positive strains were isolated in 11 
cases (16.7%).
  Distributions of patients by Child-Pugh grade were not 
significantly different between SBP patients with Gram- 
positive or Gram-negative bacteria (p=0.093). However, 
Child-Pugh and MELD scores were significantly lower in 
patients with SBP due to Gram-positive bacteria (Table 3).
  The antibiotic resistance profiles of the organisms iso-
lated are shown in Table 4. Overall, 33 of 54 (61.1%) 
Gram-negative organisms isolated showed resistance to 
ampicillin and 11 of 54 (20.4%) to ciprofloxacin. Six cas-
es (5 of 32 [15.6%] of Escherichia coli and 1 of 13 [7.7%] 
of Klebsiella pneumoniae) were resistant to cefotaxime and 
all of these 6 organisms also produced extended-spectrum 
β-lactamase (ESBL). However, all of these ESBL-produc-
ing organisms were sensitive to imipenem and mero-
penem.
3. Treatment outcome and prognosis
  Treatment response and prognosis are presented in Fig. 
1. Cefotaxime was the most frequently used antibiotics as 
a first-line treatment (150 cases, 95.5%), followed by ce-
foperazone (5 cases, 3.2%) and ciprofloxacin (2 cases, 
1.3%). First-line antibiotics were used for 9±4 days and 
follow-up paracentesis was performed at 6±5 days after 
commencement of treatments. In 24 cases (15.3%), first- 
line treatment failed: 21 of 150 cases (14.0%) treated 
with cefotaxime, 2 cases treated with ciprofloxacin (100%) 
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Fig. 1. Treatment response and in-hospital mortality of enrolled cirrhotic patients with spontaneous bacterial peritonitis (SBP). 
Fig. 2. The cumulative incidence of recurrence of spontaneous 
bacterial peritonitis after resolution.
and one of 5 cases treated with cefoperazone (20%). Of 
these 24 cases, 14 patients (58.3%) died before com-
mencement of second-line antibiotics (13 patients treated 
with cefotaxime and one patients treated with cefoper-
azone). In 2 patients treated with ciprofloxacin as a 
first-line treatment, cefotaxime was used as second-line 
antibiotic, and in 8 cases treated with cefotaxime as 
first-line treatment, meropenem (2 cases), imipenem (1), 
cefoperazone (1), ceftazidime (1), ceftriaxone (1), cipro-
floxacin (1), and teicoplanin (1) were used as second-line 
antibiotics. Second-line treatment was successful only in 3 
of 9 cases (33.3%). Multivariate analysis identified MELD 
score at admission (β, 0.123; OR, 1.131; 95% CI, 1.049- 
1.219; p=0.001) and SBP causing organism ESBL-produc-
ing organisms (β, 2.764; OR, 15.868; 95% CI, 
2.335-107.843; p=0.005) as independent predictive fac-
tors of treatment failure to first-line antibiotics.
  Thirty-three patients (21%) died during hospitalization: 
30 of 150 patients treated with cefotaxime (20%), 1 of 2 
patients treated with ciprofloxacin (50%), and 2 of 5 pa-
tients treated with ceftazidime (40%). The causes of in 
hospital mortality were hepatorenal syndrome (9 patients, 
27.3%), gastrointestinal bleeding (3 patients, 9.1%) and 
infection (21 patients, 63.6%). In-hospital mortality was 
significantly greater for patients with SBP caused by 
ESBL-producing organisms (4 of 6 patients, 66.7%) than 
in the others (29 of 151 cases, 19.2%; p=0.005). Whe-
reas 13 of 132 patients (9.8%) without treatment failure 
to first-line antibiotics died during hospitalization, 20 of 
23 patients (87%) with treatment failure died (p＜0.001).
  SBP recurred in 23 cases during 675±42 days of fol-
low-up period in 124 survivors. The cumulative inciden-
ces of SBP recurrence at 3, 6, 9 and 12 months after dis-
charge were 15.9%, 18.6%, 21.3% and 24%, respectively 
(Fig. 2). Thirty-five patients died during the follow-up pe-
riod among 124 survivors due to hepatic failure (20 cas-
es, 57.1%), gastrointestinal bleeding (7 cases, 20%), in-
fection (6 cases, 17.1%), or an intracranial hemorrhage (1 
case, 2.9%). Cumulative mortalities among survivors at 3, 
6, 9 and 12 months after an episode of SBP were 17.8%, 
24.5%, 27.1% and 27.1%, respectively, and overall mor-
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Fig. 3. The cumulative incidence of mortality in all enrolled 
patients with spontaneous bacterial peritonitis.
tality rates at 3, 6, 9 and 12 months were 36.3%, 41.5%, 
43.5% and 43.5%, respectively (Fig. 3).
4. Predictive factors of in-hospital mortality
  By multivariate analysis, the followings were significant 
independent predictive factors of in-hospital mortality: 
MELD score at admission (β, 0.105; OR, 1.110; 95% CI, 
1.049-1.175; p＜0.001), SBP by an ESBL-producing organ-
ism (β, 2.568; OR, 13.043; 95% CI, 1.667-102.066; p= 
0.014), and HCC (β, 1.110; OR, 3.034; 95% CI, 1.247- 
7.387; p=0.014). When subgroup analysis was performed 
on 96 patients without HCC, MELD score at admission 
(β, 0.168; OR, 1.183; 95% CI, 1.079-1.297; p＜0.001) 
and SBP by an ESBL-producing organism (β, 2.713; OR, 
15.069; 95% CI, 1.193-190.280; p=0.036) retained their 
significances as independent predictive factors of in-hospi-
tal mortality. 
DISCUSSION
  This multicenter retrospective study was performed to 
evaluate the current clinical features and treatment out-
comes of SBP in Korea. The major strength of this study 
was that enrollees were consecutive patients with cir-
rhosis and SBP who registered at nine medical centers 
distributed throughout Korea during 12 months period. 
Thus, our data is probably representative of the current 
clinical features of SBP in Korea. 
  According to our results, in-hospital mortality among 
cirrhotic patients with SBP was 21%, which is similar to 
that found by other recent studies.20,22,38 Although in-hos-
pital mortality in this study was significantly lower than 
data published several decades ago,16,39,40 one in five of 
our patients with SBP could not survive during hospitali-
zation. In the present study, MELD score at admission, 
the presence of HCC and SBP caused by ESBL-producing 
organisms were identified as independent predictive fac-
tors of in-hospital mortality. Of these factors, a high 
MELD score and the presence of hepatorenal carcinoma 
usually indicate the presence of more advanced liver 
disease. 
  A recent study suggested that culture-positive SBP in 
patients with cirrhosis is being caused more frequently by 
Gram-positive bacteria.31 According to this previous stu-
dy, Gram-positive bacteria caused SBP in 25% of patients 
during 1998-1999 whereas in 59% during 2000-2002.31 
However, the proportion of patients with SBP caused by 
Gram-positive strains was only 18.2%, and this finding 
concurs with a recently published single-center retro-
spective study of SBP in Korea.41 Therefore, it appears 
that profiles of causative organisms have remained sub-
stantially unchanged in Korea.
  Another recent study suggested that SBP patients with 
Gram-positive bacteria are less frequently found in Child 
class C than SBP patients with Gram-negative bacteria, 
and that they have significantly higher ascitic fluid pro-
tein and albumin concentrations.42 In another study, it 
was suggested that community-acquired SBP develops in 
patients with less advanced liver disease and was fre-
quently associated with Gram-positive bacteria.43 According 
to our results, although a smaller proportion of patients 
with SBP by Gram-positive bacteria was of Child-Pugh 
grade C, no statistical significance was observed. How-
ever, Child- Pugh score and MELD score were sig-
nificantly lower in patients with SBP by Gram-positive 
bacteria in those with SBP by Gram-negative bacteria. In 
addition, ascitic fluid protein levels were significantly 
higher in patients with SBP by Gram-positive bacteria. 
  A recent study of Korean cirrhotic patients with SBP 
suggested that a significant increase in the prevalence of 
Gram-negative bacilli resistant to cefotaxime (from 7% to 
28%) occurred between 1996 and 1999.31 However, in the 
present study, the prevalence of Gram-negative bacilli re-
sistant to cefotaxime was only 17%. Furthermore, our da-
ta is consistent with recently published data on this 
issue.41 In addition, when we considered cases of SBP in 
which causative organisms were not isolated as SBP with-
out resistance to cefotaxime, the cefotaxime resistance 
rate was only 3.8%. These findings indicate that cefotax-
ime should be considered an effective empiric treatment 
for SBP. 
  In the present study, the proportions of ESBL-produc-
ing Escherichiae coli (15.6%) and Klebsiella pneumoniae 
(7.7%) organisms were dissimilar from those found in a 
Korean study (33% and 25%, respectively, conducted in 
1999).31 However, in-line with their results,31 the prog-
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nosis of patients with SBP by ESBL-producing organisms 
was dismal with a 66.7% in-hospital mortality rate. Since 
SBP by ESBL-producing organisms was an independent 
predictive factor of treatment failure and in-hospital mor-
tality, rapid changes to appropriate antibiotics might be 
needed. ESBL-producing organisms are resistant to all an-
tibiotics, except imipenem and meropenem. Therefore, 
when ESBL-producing organisms were to be identified 
cultured or when no clinical or laboratory improvement 
was to be noted on 3rd-generation cephalosporin, a 
prompt change of antibiotics to imipenem or meropenem 
should be considered. 
  The present study showed a high prevalence of Gram- 
negative organisms resistant to ciprofloxacin (20.8%), 
which was consistent with the findings of a recent 
study.31 Moreover, it has been suggested in several pre-
vious studies that the long-term administration of nor-
floxacin was highly effective in preventing SBP recur-
rence.23,44,45 Furthermore, a recently issued guideline rec-
ommends long- term prophylaxis with daily norfloxacin in 
patients who have survived an episode of SBP.46 However, 
norfloxacin prophylaxis could increase the frequency of 
SBP by quinolone-resistant bacteria, and some authors 
have reported the development of quinolone-resistant 
Gram-negative bacilli in the feces of cirrhotic patients on 
long-term norfloxacin prophylaxis.27,34 Quinolone is one of 
the most commonly used antibiotic in Korean out-patient 
clinics and therefore, the widespread use of quinolone 
might explain the high prevalence of quinolone-resistance 
observed in the present study, although only 8 cases had 
received norfloxacin prophylaxis according to a careful re-
view of medical records.
  We concluded that despite recent improvements in di-
agnosis and treatment, SBP was still associated with sig-
nificant mortality in patients with cirrhosis, especially in 
patients with a high MELD score. In addition, the study 
indicated that cefotaxime was a good empiric treatment 
for SBP. However, in cases of treatment failure an anti-
biotic change to imipenem or meropenem should be con-
sidered. 
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